tiprankstipranks
Top Stocks
U.S. Stock Market OverviewTop Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
Top ETFs by AUMSPY ETFQQQ ETF
Stock Comparison
Energy StocksOil StocksBest Value StocksAirline StocksElectric Vehicle StocksMATANA Stocks
New
Bank StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
Global Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsPre-Market BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsTools for Trading PlatformsData for Hedge FundsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Top ETFs by AUM
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
U.S. Markets
Market Movers
Expert Center
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
Top ETFs by AUM
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Energy Stocks
EV Stocks
Crypto News
Dividend Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Pre-Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

AZN Stock Latest News

AstraZeneca continuing to work with FDA to collect data on Evusheld and variants
The FlyAstraZeneca continuing to work with FDA to collect data on Evusheld and variants
1d ago
AZN
FDA announces Evusheld not currently authorized for emergency use in U.S.
The FlyFDA announces Evusheld not currently authorized for emergency use in U.S.
1d ago
AZN
AstraZeneca, Daiichi Sankyo receive EU approval for Enhertu
The FlyAstraZeneca, Daiichi Sankyo receive EU approval for Enhertu
2d ago
AZN
Novartis downgraded to Neutral from Buy at Citi
The FlyNovartis downgraded to Neutral from Buy at Citi
2d ago
AZN
Thermo Fisher, AstraZeneca team on CDx test for Tagrisso
The FlyThermo Fisher, AstraZeneca team on CDx test for Tagrisso
3d ago
AZN
TMO
Cantor biotech/biopharma analysts hold analyst/industry conference call
The FlyCantor biotech/biopharma analysts hold analyst/industry conference call
4d ago
AZN
ARVN
AstraZeneca commences tender offer to acquire CinCor Pharma for $26.00 per share
The FlyAstraZeneca commences tender offer to acquire CinCor Pharma for $26.00 per share
4d ago
AZN
CINC
Biotech Alert: Searches spiking for these stocks today
The FlyBiotech Alert: Searches spiking for these stocks today
8d ago
AIM
AZN
AstraZeneca price target raised to 126 GBp from 118 GBp at Berenberg
The FlyAstraZeneca price target raised to 126 GBp from 118 GBp at Berenberg
9d ago
AZN
Hutchmed announces inclusion of ORPATHYS in China’s NRDL
The FlyHutchmed announces inclusion of ORPATHYS in China’s NRDL
9d ago
AZN
HCM
AIM ImmunoTech in pancreatic cancer research pacts with AstraZeneca
The FlyAIM ImmunoTech in pancreatic cancer research pacts with AstraZeneca
10d ago
AIM
AZN
AstraZeneca’s Tezspire approved in E.U. in for severe asthma
The FlyAstraZeneca’s Tezspire approved in E.U. in for severe asthma
14d ago
AZN
Arvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks
The FlyArvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks
15d ago
AZN
LLY
CinCor Pharma downgraded to Equal Weight from Overweight at Barclays
The FlyCinCor Pharma downgraded to Equal Weight from Overweight at Barclays
16d ago
AZN
CINC
AstraZeneca’s Airsupra approved in U.S. for asthma
The FlyAstraZeneca’s Airsupra approved in U.S. for asthma
16d ago
AZN
CinCor Surges after Acquisition by AstraZeneca
Market NewsCinCor Surges after Acquisition by AstraZeneca
18d ago
AZN
CINC
AstraZeneca to acquire CinCor Pharma for at least $1.3B
The FlyAstraZeneca to acquire CinCor Pharma for at least $1.3B
19d ago
AZN
CINC
Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
The FlyStreet Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
22d ago
APP
AXP
Sanofi says FDA accepts BLA for nirsevimab
The FlySanofi says FDA accepts BLA for nirsevimab
22d ago
AZN
SNY
AstraZeneca’s BLA for nirsevimab in RSV prevention accepted by FDA for review
The FlyAstraZeneca’s BLA for nirsevimab in RSV prevention accepted by FDA for review
22d ago
AZN
AstraZeneca initiated with an Outperform at BMO Capital
The FlyAstraZeneca initiated with an Outperform at BMO Capital
23d ago
AZN
Kymera Therapeutics appoints Chiniara as CLO, Corporate Secretary
The FlyKymera Therapeutics appoints Chiniara as CLO, Corporate Secretary
23d ago
AZN
KYMR
AstraZeneca price target raised to 13,500 GBp from 12,500 GBp at JPMorgan
The FlyAstraZeneca price target raised to 13,500 GBp from 12,500 GBp at JPMorgan
24d ago
AZN
AstraZeneca announces Calquence approved in Japan to treat CLL
The FlyAstraZeneca announces Calquence approved in Japan to treat CLL
1M ago
AZN
AstraZeneca announces Imfinzi, Imjudo approved in Japan to treat three cancers
The FlyAstraZeneca announces Imfinzi, Imjudo approved in Japan to treat three cancers
1M ago
AZN
AstraZeneca’s Lynparza approved in E.U. as first line treatment in mCRPC
The FlyAstraZeneca’s Lynparza approved in E.U. as first line treatment in mCRPC
1M ago
AZN
MRK
Merck, AstraZeneca: LYNPARZA/abiraterone and prednisone combo approved in EU
The FlyMerck, AstraZeneca: LYNPARZA/abiraterone and prednisone combo approved in EU
1M ago
AZN
MRK
AstraZeneca’s Imfinzi+chemotherapy approved in E.U. in BTC patients
The FlyAstraZeneca’s Imfinzi+chemotherapy approved in E.U. in BTC patients
1M ago
AZN
AstraZeneca, G42 Healthcare enter strategic partnership agreement
The FlyAstraZeneca, G42 Healthcare enter strategic partnership agreement
1M ago
AZN
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.